PWE-124 Daily aspirin 300mg: how much do patients take? drug accountability for the first 5 years of the aspect study

<h3>Introduction</h3> We prescribe medicines to patients but the key factor determining efficacy is the dose taken. Recent evidence suggests compliance with aspirin therapy is vital to ensuring its chemoprevention efficacy. Therefore we look at the patient’s compliance with aspirin in a large trial. <h3>Method</h3> In the 2 × 2 factorial AspECT study, Barrett’s patients were randomised to take 300 mg Aspirin daily or no aspirin and to take 20 mg or 80 mg of PPI. This paper describes for the first 5 years after randomisation the aspirin taking pattern of those prescribed aspirin. Logistic regression analysis was used to consider what factors affected compliance. <h3>Results</h3> Of the 1116 patients randomised to aspirin, 803 (72%; 95% CI 69.2, 74.5) took aspirin…